The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...
In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Health and Me on MSN3d
FDA Approves Tremfya For Active Crohn's DiseaseCrohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...
US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback